Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 7/20 | 0.33 |
| ▸ | KRAS | P01116 | 5/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ACP3 | P15309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606527 | 0.86 | IDH1 (0.42) | IDH1HSD11B1MAPTTNFPSMB8 | |
| SCHEMBL1606605 | 0.86 | IDH1 (0.42) | IDH1HSD11B1MAPTTNFPSMB8 | |
| SCHEMBL5464521 | 0.86 | IDH1 (0.42) | IDH1HSD11B1MAPTTNFPSMB8 | |
| SCHEMBL1605884 | 0.83 | MAPKAPK2 (0.45) | IDH1ALDH1A1MAPTMAPKAPK2 | |
| SCHEMBL14429409 | 0.81 | HTT (0.39) | HSD11B1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL10252680 | 0.81 | HTR6 (0.36) | HSD11B1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL10249360 | 0.81 | HTR6 (0.36) | HSD11B1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL4395222 | 0.81 | HTR6 (0.36) | HSD11B1ALDH1A1MAPTHSD17B10 | |
| SCHEMBL14440290 | 0.79 | KMT2A (0.46) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1605153 | 0.77 | TAAR1 (0.47) | IDH1ALDH1A1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-1951695-B1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1951695-A1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007061661-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061600-A1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | IDH1 191/4885HSD11B1 1/4885ALDH1A1 71/4885 |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | SRD5A1, HSD11B1, HSD3B1 | IDH1 94/4885HSD11B1 2/4885ALDH1A1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.